9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies

Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies

Chronic Kidney Disease (CKD) affects more than 1 in 7 adults in the United States (~37 million people) and represents a major multiplier of cardiovascular morbidity and all-cause mortality. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), board certification requires a thorough mastery of KDIGO (Kidney Disease: Improving Global Outcomes) diagnostic criteria and staging, precise interpretation of the urine albumin-to-creatinine ratio (UACR), evidence-based implementation of multi-drug renoprotective regimens, vigilant surveillance and treatment of CKD complications, and timely referral for nephrology co-management and renal replacement therapy (RRT) planning.

---

1. Definition, Diagnostic Criteria & Pathophysiology of CKD

KDIGO Diagnostic Definition

CKD is defined as abnormalities of kidney structure or function persisting for at least 3 continuous months with implications for health. A transient decline in glomerular filtration rate (GFR) or temporary proteinuria resulting from acute illness, fever, or volume depletion does not constitute CKD.

+-----------------------------------------------------------------------------+
|                        KDIGO CRITERIA FOR CKD (>= 3 MONTHS)                 |
|                                                                             |
|   EITHER OF THE FOLLOWING CRITERIA PRESENT PERSISTENTLY FOR > 3 MONTHS:      |
|                                                                             |
|   1. DECREASED GLOMERULAR FILTRATION RATE:                                  |
|      - eGFR < 60 mL/min/1.73 m2 (Stages G3a, G3b, G4, or G5)                |
|                                                                             |
|                                    OR                                       |
|                                                                             |
|   2. ONE OR MORE MARKERS OF KIDNEY DAMAGE:                                  |
|      - Albuminuria: Urine Albumin-to-Creatinine Ratio (UACR) >= 30 mg/g     |
|        (or >= 3 mg/mmol; 24-hr urine albumin >= 30 mg/24 hr).               |
|      - Urine Sediment Abnormalities: Persistent dysmorphic RBCs, RBC casts, |
|        WBC casts, granular casts, or fatty casts / oval fat bodies.         |
|      - Tubular Disorders: Renal tubular acidosis, nephrogenic DI, Bartter.  |
|      - Histopathological Abnormalities: Biopsy-proven glomerulonephritis,   |
|        amyloidosis, interstitial fibrosis, or Kimmelstiel-Wilson nodules.   |
|      - Structural Abnormalities on Imaging: Polycystic kidneys, hydroneph-  |
|        rosis, renal artery stenosis, cortical thinning, small echogenic kidneys.|
|      - History of Kidney Transplantation.                                   |
+-----------------------------------------------------------------------------+

Primary Etiologies of CKD in Adults

1. Diabetic Kidney Disease (DKD / Diabetic Nephropathy): Leading cause (~40–50% of ESRD cases). Driven by chronic hyperglycemia, advanced glycation end-products (AGEs), reactive oxygen species, and hyperfiltration.
2. Hypertensive Nephrosclerosis: Second leading cause (~25–30%). Chronic systemic hypertension transmits elevated pressures into renal microvasculature, producing medial hypertrophy, hyaline arteriolosclerosis, glomerular ischemia, and focal segmental glomerulosclerosis.
3. Glomerulonephritis: IgA Nephropathy (Berger disease; most common primary glomerulonephritis worldwide), Membranous Nephropathy, Focal Segmental Glomerulosclerosis (FSGS), Lupus Nephritis, and ANCA-associated vasculitis.
4. Autosomal Dominant Polycystic Kidney Disease (ADPKD): Mutations in PKD1 (chromosome 16) or PKD2 (chromosome 4) causing bilateral progressive cystic enlargement.
5. Chronic Tubulointerstitial Nephritis & Toxicities: Chronic NSAID exposure, calcineurin inhibitors (cyclosporine, tacrolimus), chronic lithium therapy, heavy metals, or recurrent pyelonephritis/obstructive uropathy.

Pathophysiological Cascade: Hyperfiltration & Glomerular Sclerosis

Regardless of the initiating insult, the progressive loss of functional nephrons triggers compensatory adaptive mechanisms in surviving nephrons that ultimately prove maladaptive.

+-----------------------------------------------------------------------------+
|                  MALADAPTIVE NEPHRON LOSS & PROGRESSION CASCADE             |
|                                                                             |
|   Primary Renal Insult (e.g., Diabetes, Hypertension, Glomerulonephritis)   |
|                                     |                                       |
|                                     v                                       |
|                  Loss of Functional Nephron Mass (Nephron Loss)             |
|                                     |                                       |
|                                     v                                       |
|       Compensatory Hypertrophy & Hyperfiltration in Surviving Nephrons      |
|         - Preferential EFFERENT arteriolar vasoconstriction (Angiotensin II)|
|         - Afferent arteriolar vasodilation (Prostaglandins, Nitric Oxide)   |
|                                     |                                       |
|                                     v                                       |
|        Elevated Intraglomerular Capillary Hydrostatic Pressure (P_gc)       |
|                                     |                                       |
|                                     v                                       |
|         Disruption of Podocyte Slit Diaphragm & Glomerular Basement         |
|            Membrane (GBM) -> ACCELERATED ALBUMINURIA / PROTEINURIA          |
|                                     |                                       |
|                                     v                                       |
|          Filtered Albumin & Cytokines Trigger Proximal Tubular Injury       |
|                 -> Tubulointerstitial Inflammation & Fibrosis               |
|                                     |                                       |
|                                     v                                       |
|             GLOMERULOSCLEROSIS & PROGRESSIVE DECLINE IN eGFR                |
+-----------------------------------------------------------------------------+

---

2. KDIGO 2D Staging & Prognostic Risk Matrix (G1–G5 and A1–A3)

KDIGO guidelines mandate a two-dimensional classification system combining the GFR category (G1–G5) with the Albuminuria category (A1–A3). Staging solely by eGFR fails to capture the dramatic cardiovascular and renal risk imparted by albuminuria.

+---------------------------------------------------------------------------------------------------+
|                               KDIGO 2D PROGNOSTIC RISK MATRIX                                     |
|                                                                                                   |
|   GFR STAGES                    A1: Normal/Mild          A2: Moderate            A3: Severe       |
|   (mL/min/1.73 m2)              UACR < 30 mg/g           UACR 30-300 mg/g        UACR > 300 mg/g  |
|   ---------------------------------------------------------------------------------------------   |
|   G1: Normal/High (>= 90)       [ LOW RISK ]             [ MODERATE RISK ]       [ HIGH RISK ]    |
|   G2: Mildly Reduced (60-89)    [ LOW RISK ]             [ MODERATE RISK ]       [ HIGH RISK ]    |
|   G3a: Mild-to-Mod (45-59)      [ MODERATE RISK ]        [ HIGH RISK ]           [ VERY HIGH ]    |
|   G3b: Mod-to-Severe (30-44)    [ HIGH RISK ]            [ VERY HIGH RISK ]      [ VERY HIGH ]    |
|   G4: Severely Reduced (15-29)  [ VERY HIGH RISK ]       [ VERY HIGH RISK ]      [ VERY HIGH ]    |
|   G5: Kidney Failure (< 15)     [ VERY HIGH RISK ]       [ VERY HIGH RISK ]      [ VERY HIGH ]    |
+---------------------------------------------------------------------------------------------------+\n```

### Clinical Staging Categories & Terminology
- **G1:** Normal or high GFR ($\ge 90\text{ mL/min}/1.73\text{ m}^2$) — Requires structural damage (e.g., $UACR \ge 30\text{ mg/g}$) to be diagnosed as CKD.
- **G2:** Mildly decreased GFR ($60\text{--}89\text{ mL/min}/1.73\text{ m}^2$) — Requires structural damage to meet CKD definition.
- **G3a:** Mildly to moderately decreased GFR ($45\text{--}59\text{ mL/min}/1.73\text{ m}^2$).
- **G3b:** Moderately to severely decreased GFR ($30\text{--}44\text{ mL/min}/1.73\text{ m}^2$).
- **G4:** Severely decreased GFR ($15\text{--}29\text{ mL/min}/1.73\text{ m}^2$) — High risk of progression; mandate vascular access planning.
- **G5:** Kidney Failure / End-Stage Kidney Disease ($< 15\text{ mL/min}/1.73\text{ m}^2$ or dialysis dependency).

### Albuminuria Quantification (UACR vs. 24-Hour Urine Collection)
- The **random spot Urine Albumin-to-Creatinine Ratio (UACR)** in an early morning specimen is the gold standard for clinical screening and monitoring. Spot UACR in $\text{mg/g}$ accurately correlates with 24-hour total albumin excretion in $\text{mg/24 hours}$:
  - **A1 (Normal to Mildly Increased):** $UACR < 30\text{ mg/g}$ ($< 3\text{ mg/mmol}$).
  - **A2 (Moderately Increased):** $UACR = 30\text{--}300\text{ mg/g}$ ($3\text{--}30\text{ mg/mmol}$). *Note: The historical term "microalbuminuria" is deprecated by KDIGO/ADA; use "moderately increased albuminuria."*
  - **A3 (Severely Increased):** $UACR > 300\text{ mg/g}$ ($> 30\text{ mg/mmol}$). Includes nephrotic range ($UACR > 2,200\text{ mg/g}$ or total proteinuria $> 3.5\text{ g/day}$). *Historical term "macroalbuminuria" is deprecated.* 

> [!TIP]
> **Diagnostic Confirmation Protocol:** To establish persistent albuminuria, at least **2 of 3 spot UACR specimens** collected over a 3- to 6-month period must be elevated, as transient albuminuria can be induced by strenuous exercise, fever, acute urinary tract infection, severe hyperglycemia, or congestive heart failure exacerbation.

---

## 3. Evidence-Based Renoprotective Pharmacotherapy

The management of CKD has evolved from passive monitoring to active multi-pathway pharmacotherapy aimed at slowing eGFR decline, reducing intraglomerular pressure, halting albuminuria, and lowering cardiovascular mortality.

+-----------------------------------------------------------------------------+ | PILLARS OF EVIDENCE-BASED RENOPROTECTIVE PHARMACOTHERAPY | | | | 1. RAAS INHIBITION (ACEi or ARB Monotherapy) | | - Indication: Hypertension + Albuminuria (UACR >= 30 in DM; >= 300 in | | non-DM; or >= 30 in non-DM if HTN present). | | - Action: Dilates efferent arteriole -> drops P_gc. | | | | 2. SGLT2 INHIBITORS (Empagliflozin, Dapagliflozin, Canagliflozin) | | - Indication: CKD with eGFR >= 20 mL/min/1.73 m2 + UACR >= 200 mg/g | | (with or without Type 2 Diabetes; DAPA-CKD, EMPA-KIDNEY trials). | | - Action: Restores tubuloglomerular feedback -> constricts afferent art.| | | | 3. NON-STEROIDAL MRAs (Finerenone) | | - Indication: T2D + CKD (eGFR >= 25 + UACR >= 30) on max tolerated | | ACEi/ARB with serum K <= 4.8 mEq/L (FIDELIO-DKD, FIGARO-DKD). | | - Action: Blocks mineralocorticoid receptor inflammation and fibrosis. | | | | 4. GLP-1 RECEPTOR AGONISTS (Semaglutide, Dulaglutide) | | - Indication: T2D + CKD with inadequate glycemic control or high CV | | risk (FLOW trial; reduces renal outcomes and CV mortality). | +-----------------------------------------------------------------------------+

### Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors
- **Mechanism:** Angiotensin-Converting Enzyme Inhibitors (ACEi, e.g., Lisinopril, Enalapril) and Angiotensin II Receptor Blockers (ARBs, e.g., Losartan, Valsartan) selectively block Angiotensin II action on $\text{AT}_1$ receptors, causing **preferential dilation of the efferent arteriole**. This reduces intraglomerular capillary hydrostatic pressure ($P_{\text{gc}}$), diminishes glomerular mechanical shear stress, and halts podocyte detachment.
- **Blood Pressure Targets:** KDIGO recommends a target systolic blood pressure **$< 120\text{ mmHg}$** (using standardized office measurement) when tolerated. The ADA recommends a target **$< 130/80\text{ mmHg}$** for patients with diabetes and CKD.
- **The "Acceptable Creatinine Bump" Rule:** Following initiation or dose escalation of an ACEi or ARB, a transient acute drop in eGFR or a **serum creatinine increase up to 30% from baseline** is expected and represents a favorable hemodynamic reduction in glomerular hypertension. 
  - **Clinical Decision Rule:** Do **NOT** discontinue the ACEi/ARB if creatinine rises $\le 30\%$ and stabilizes. Recheck labs in 2–4 weeks. Only reduce dose or discontinue if creatinine rises $>30\%$, if refractory hyperkalemia occurs ($K^+ > 5.5\text{--}6.0\text{ mEq/L}$ despite medical therapy), or if severe symptomatic hypotension develops.
  - A creatinine spike $>30\%$ suggests underlying **bilateral renal artery stenosis** (or unilateral stenosis in a solitary kidney) or severe intravascular volume depletion.
- **Strict Contraindication:** **Dual RAAS Blockade** (concurrent use of ACEi + ARB, or RAAS inhibitor + Direct Renin Inhibitor [Aliskiren]) is **strictly contraindicated** due to high risks of hyperkalemia, acute kidney injury, and hypotension without incremental cardiovascular or renal benefit (demonstrated in ONTARGET and VA NEPHRON-D trials).

### Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
- **Mechanism of Renoprotection:** SGLT2 inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) block the reabsorption of filtered glucose and sodium in the proximal convoluted tubule (PCT). Increased delivery of sodium and chloride to the **macula densa** in the juxtaglomerular apparatus stimulates adenosine release, restoring **tubuloglomerular feedback (TGF)**. This induces **afferent arteriolar vasoconstriction**, reducing intraglomerular hypertension and reversing hyperfiltration.

+-----------------------------------------------------------------------------+ | GLOMERULAR HEMODYNAMICS: RAAS INHIBITORS vs. SGLT2 INHIBITORS | | | | AFFERENT ARTERIOLE EFFERENT ARTERIOLE | | (Inflow) (Outflow) | | | ^ | | v | | | +-----------+ +-----------+ | | | GLOMERULAR CAPILLARY BED (P_gc) | | | | +-----------+ +-----------+ | | ^ ^ | | | | | | [ SGLT2 INHIBITORS ] [ RAAS INHIBITORS ] | | - Increases Na+ to macula densa - Blocks Angiotensin II effect | | - Causes AFFERENT VASOCONSTRICTION - Causes EFFERENT VASODILATION | | - Reduces high blood inflow - Opens outflow valve | | | | ---> SYNERGISTIC RESULT: Dramatic Reduction in Intraglomerular Pressure, | | Halting Albuminuria and Slowing Long-Term eGFR Loss! | +-----------------------------------------------------------------------------+

- **Clinical Indications & Initiation Thresholds:**
  - Initiate in patients with CKD Stage G2–G4 (eGFR $\ge 20\text{--}25\text{ mL/min}/1.73\text{ m}^2$) and $UACR \ge 200\text{ mg/g}$ (or with Type 2 Diabetes at any level of albuminuria).
  - **Continuation:** Once initiated, SGLT2 inhibitors may be safely continued even if eGFR falls below $20\text{ mL/min}/1.73\text{ m}^2$, until dialysis or kidney transplantation is initiated.
- **Adverse Effects & Clinical Safety:**
  - Mycotic genital infections (candidiasis; counsel on perineal hygiene).
  - Euglycemic Diabetic Ketoacidosis (euDKA): Hold SGLT2 inhibitors **3 to 4 days prior to elective major surgical procedures** or during acute severe medical illness/prolonged fasting.
  - Modest initial "dip" in eGFR ($2\text{--}4\text{ mL/min}$) within 2–4 weeks is reversible and expected.

### Non-Steroidal Mineralocorticoid Receptor Antagonists (Finerenone)
- **Mechanism:** Finerenone selectively and non-steroidally binds to mineralocorticoid receptors (MR) in the kidney and vasculature with higher affinity than spironolactone or eplerenone, suppressing MR-mediated inflammation, endothelial dysfunction, and fibrosis without causing anti-androgenic side effects (gynecomastia).
- **Indications:** FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with **Type 2 Diabetes associated with CKD** ($eGFR \ge 25\text{ mL/min}/1.73\text{ m}^2$ and $UACR \ge 30\text{ mg/g}$) who are already taking maximally tolerated doses of an ACEi or ARB.
- **Potassium Thresholds:** Baseline serum potassium must be **$\le 4.8\text{ mEq/L}$** before initiation. If potassium is $4.9\text{--}5.0\text{ mEq/L}$, optimize other therapies first. Recheck potassium and eGFR at 4 weeks. Withhold if $K^+ > 5.5\text{ mEq/L}$ and resume at a lower dose when $K^+ \le 5.0\text{ mEq/L}$.

---

## 4. Comprehensive Management of CKD Complications

As functioning nephron mass declines below 50% ($eGFR < 60\text{ mL/min}$), kidneys fail to maintain endocrine, metabolic, and fluid-electrolyte balance, leading to systemic multiorgan complications.

+-----------------------------------------------------------------------------+ | CHRONIC COMPLICATIONS OF CKD | | | | 1. ANEMIA OF CKD | | - Deficient peritubular Erythropoietin (EPO) + Iron deficiency. | | - Target TSAT > 20%, Ferritin > 100 ng/mL; ESA target Hb 10.0-11.5 g/dL| | | | 2. CKD-MINERAL & BONE DISORDER (CKD-MBD) | | - Low 1,25(OH)2D3 (Calcitriol) + Phosphate retention -> Low Ca2+ | | - Elevated FGF-23 -> Secondary Hyperparathyroidism (PTH elevation) | | - Renal Osteodystrophy & Severe Vascular / Soft Tissue Calcification. | | | | 3. METABOLIC ACIDOSIS | | - Inability to excrete fixed H+ and regenerate HCO3- (Serum HCO3 < 22).| | - Triggers muscle wasting, bone resorption; Treat with Oral NaHCO3. | | | | 4. HYPERKALEMIA | | - Decreased distal K+ excretion; Treat with low-K diet, loop diuretics, | | novel potassium binders (Patiromer, Lokelma) to maintain RAASi. | | | | 5. VOLUME OVERLOAD & HYPERTENSION | | - Sodium and water retention; Loop diuretics (Furosemide, Torsemide). | +-----------------------------------------------------------------------------+

### Anemia of Chronic Kidney Disease
- **Pathophysiology:** Primarily caused by decreased synthesis of **erythropoietin (EPO)** by peritubular interstitial fibroblasts in the renal cortex. Secondary contributors include absolute and functional iron deficiency, systemic inflammation elevating **hepcidin** (blocking intestinal iron absorption and macrophage iron release), and uremic toxins reducing red blood cell lifespan from 120 days to 60–90 days.
- **Diagnostic Evaluation:** Evaluated when $Hb < 13.0\text{ g/dL}$ in men or $< 12.0\text{ g/dL}$ in women. Classically presents as a **normochromic, normocytic anemia**. Required diagnostic workup includes: Complete Blood Count (CBC) with red blood cell indices, reticulocyte count, **Serum Ferritin**, **Transferrin Saturation (TSAT)**, serum Vitamin B12, and serum Folate.

$$TSAT (\%) = \frac{\text{Serum Iron (mcg/dL)}}{\text{Total Iron Binding Capacity [TIBC] (mcg/dL)}} \times 100$$

- **Iron Repletion Goals (KDIGO):**
  - Prior to initiating any ESA therapy, iron deficiency must be corrected. Target a **TSAT $> 20\%$** (ideally 20–30%) and **Serum Ferritin $> 100\text{ ng/mL}$** in non-dialysis CKD ($> 200\text{ ng/mL}$ in hemodialysis patients).
  - Oral iron (e.g., Ferrous sulfate, Ferrous gluconate, Ferric citrate) can be trialed in non-dialysis CKD; IV iron (e.g., Iron sucrose, Ferric carboxymaltose) is preferred if oral iron is poorly tolerated, ineffective, or if $TSAT \le 20\%$.
- **Erythropoiesis-Stimulating Agents (ESAs: Epoetin alfa, Darbepoetin alfa):**
  - **Initiation Threshold:** In non-dialysis CKD, consider ESA initiation **only when $Hb < 10.0\text{ g/dL}$**, and only after ensuring adequate iron stores ($TSAT > 20\%$, Ferritin $> 100\text{ ng/mL}$).
  - **Target Hemoglobin Range:** Maintain Hb strictly between **$10.0\text{ and }11.5\text{ g/dL}$**.

> [!WARNING]
> **Black Box Warning — ESA Safety & Overtreatment Risks:**
> ESAs must **NEVER** be used to target a "normal" hemoglobin level ($> 11.5\text{--}12.0\text{ g/dL}$). Large prospective randomized trials (CHOIR, CREATE, TREAT) demonstrated that targeting Hb $>12.0\text{ g/dL}$ produces a statistically significant increase in **ischemic stroke, myocardial infarction, venous thromboembolism, vascular access thrombosis, accelerated tumor progression, and cardiovascular death**. If Hb approaches $11.5\text{ g/dL}$, reduce the ESA dose by 25–50%; if Hb exceeds $11.5\text{ g/dL}$, withhold ESA therapy until Hb declines below $11.0\text{ g/dL}$.

### CKD-Mineral and Bone Disorder (CKD-MBD)
- **Pathophysiology:** As GFR declines below $45\text{ mL/min}$:
  1. **Phosphate Retention:** Diseased nephrons cannot excrete daily dietary phosphorus, driving hyperphosphatemia.
  2. **FGF-23 Elevation:** Osteocytes secrete Fibroblast Growth Factor 23 (FGF-23) to force renal phosphate excretion; high FGF-23 further suppresses renal 1-alpha-hydroxylase.
  3. **Calcitriol Deficiency:** Diminished renal parenchymal 1-alpha-hydroxylase activity reduces conversion of 25-hydroxyvitamin D to active **1,25-dihydroxyvitamin D ($1,25(\text{OH})_2\text{D}_3$ / Calcitriol)**, decreasing gut calcium absorption and resulting in hypocalcemia.
  4. **Secondary Hyperparathyroidism:** Hypocalcemia, hyperphosphatemia, and low calcitriol chronically stimulate the parathyroid glands, producing parathyroid hyperplasia and elevated **Intact PTH (iPTH)**.
  5. **Skeletal & Vascular Consequences:** High PTH drives high-turnover bone disease (**Osteitis Fibrosa Cystica**), osteomalacia, pathological fractures, severe medial arterial calcification (**Monckeberg arteriosclerosis**) and Calciphylaxis.

+-----------------------------------------------------------------------------+ | CKD-MBD PATHOPHYSIOLOGICAL SPIRAL | | | | Declining GFR (< 45 mL/min/1.73 m2) | | | | | | v v | | [Phosphate Retention] [Loss of 1-alpha-hydroxylase] | | | | | | v v | | [Elevated FGF-23] [Low Active Calcitriol] | | | | | | +---------------+---------------+ | | | | | v | | [HYPOCALCEMIA] | | | | | v | | [SECONDARY HYPERPARATHYROIDISM (Elevated PTH)] | | | | | | v v | | [Bone Resorption & Fragility] [Vascular & Soft Tissue Calcif.] | | - Osteitis Fibrosa Cystica - Accelerated Atherosclerosis | | - Adynamic Bone Disease - Calciphylaxis (Ischemic necrosis| +-----------------------------------------------------------------------------+

- **Management Protocol for CKD-MBD:**
  - **Dietary Phosphorus Restriction:** Limit dietary phosphate to **$800\text{--}1,000\text{ mg/day}$** (limit processed foods containing inorganic phosphate additives, colas, dairy, nuts).
  - **Phosphate Binders (Taken WITH Meals):**
    - *Calcium-Based Binders (Calcium Acetate, Calcium Carbonate):* First-line if serum calcium is low/normal. Avoid if hypercalcemic or if extensive arterial calcification is present (max elemental calcium $1,500\text{ mg/day}$ from binders).
    - *Non-Calcium Binders (Sevelamer Carbonate, Lanthanum Carbonate):* Preferred if serum calcium is elevated or patient has documented vascular calcification. (Sevelamer also binds bile acids, moderately lowering LDL-C).
  - **Vitamin D & Analogs:** Correct nutritional 25-OH Vitamin D deficiency ($<30\text{ ng/mL}$) with Cholecalciferol or Ergocalciferol. If PTH remains elevated despite normal vitamin D and phosphate control, initiate active Vitamin D receptor activators (**Calcitriol**, Paricalcitol).
  - **Calcimimetics (Cinacalcet, Etelcalcetide):** Allosterically activate calcium-sensing receptors on the parathyroid gland, suppressing PTH secretion without increasing serum calcium or phosphate (ideal for dialysis patients with hypercalcemic hyperparathyroidism).

### Chronic Metabolic Acidosis
- **Pathophysiology:** Loss of functioning nephrons impairs tubular ammonium ($\text{NH}_4^+$) excretion and endogenous bicarbonate regeneration, resulting in normal anion gap or high anion gap metabolic acidosis.
- **Consequences:** Chronic acidosis stimulates muscle protein catabolism, accelerates bone demineralization (bone buffers acid, releasing calcium), exacerbates hyperkalemia, and independently accelerates CKD progression.
- **Treatment Target:** Maintain serum bicarbonate **$\ge 22\text{ mEq/L}$** (normal: 22–29 mEq/L).
- **Pharmacotherapy:** Prescribe oral **Sodium Bicarbonate** (e.g., 650 mg to 1,300 mg orally twice to three times daily; 1 gram of $\text{NaHCO}_3 \approx 12\text{ mEq}$ of bicarbonate). Monitor for volume overload and hypertension due to sodium load.

### Hyperkalemia Management
- **Mechanisms:** Diminished distal tubular flow and potassium secretion, hyporeninemic hypoaldosteronism, metabolic acidosis shifting intracellular $\text{K}^+$ outward, and renoprotective RAAS inhibitors.
- **Strategies to Maintain RAASi Therapy:** Avoid discontinuing beneficial ACEi/ARB/MRA therapy for mild-to-moderate hyperkalemia ($5.1\text{--}5.5\text{ mEq/L}$). Instead, implement:
  1. Dietary potassium restriction ($< 2,000\text{--}3,000\text{ mg/day}$).
  2. Addition or up-titration of loop diuretics (e.g., Furosemide $40\text{--}80\text{ mg}$ daily) to promote kaliuresis.
  3. Non-absorbed potassium-binding exchange polymers: **Patiromer (Veltassa)** ($8.4\text{ g}$ daily with food) or **Sodium Zirconium Cyclosilicate (Lokelma / SZC)** ($5\text{--}10\text{ g}$ daily). Lokelma binds $\text{K}^+$ in exchange for $\text{Na}^+$ throughout the GI tract, rapidly restoring normokalemia within 1–2 hours without causing colonic necrosis (which occurred with historical sodium polystyrene sulfonate [Kayexalate] in sorbitol).

---

## 5. Nephrology Referral Triggers & Renal Replacement Therapy Preparation

### Standardized KDIGO Nephrology Referral Criteria
The AGPCNP must initiate prompt referral to a nephrologist when any of the following criteria are met:

+-----------------------------------------------------------------------------+ | KDIGO NEPHROLOGY REFERRAL TRIGGERS | | | | * eGFR < 30 mL/min/1.73 m2 (CKD Stage G4 or G5). | | * Severely Increased Albuminuria: UACR > 300 mg/g (> 30 mg/mmol) or | | Nephrotic-range Proteinuria (> 2,200 mg/g or > 3.5 g/24 hours). | | * Rapid Progression of CKD: Sustained decline in eGFR > 5 mL/min/1.73 m2/ | | year, or a > 25% drop in eGFR from baseline within 12 months. | | * Unexplained Microscopic Hematuria with dysmorphic RBCs or RBC casts | | (suggests active glomerulonephritis or vasculitis). | | * Resistant Hypertension: BP uncontrolled despite >= 3 antihypertensive | | agents of different classes (including a diuretic) at maximum doses. | | * Persistent refractory electrolyte disturbances (hyperkalemia, acidosis).| | * Hereditary kidney disease (e.g., ADPKD) or recurrent complex nephrolithiasis.| | * Inability to determine underlying etiology of kidney disease. | +-----------------------------------------------------------------------------+

### Renal Replacement Therapy (RRT) Modalities & Vascular Access Planning
- **Timely Preparation:** When eGFR declines below **$20\text{--}25\text{ mL/min}/1.73\text{ m}^2$ (Stage G4)**, initiate formal multidisciplinary education regarding RRT options:
  1. **Pre-Emptive Kidney Transplantation:** Living donor or deceased donor kidney transplantation prior to dialysis initiation provides superior long-term survival, quality of life, and cost-effectiveness compared to dialysis.
  2. **Hemodialysis (HD) & Vascular Access Creation:**
     - **Arteriovenous (AV) Fistula:** The gold-standard permanent hemodialysis access (typically radiocephalic or brachiocephalic anastomosis). Constructed in the non-dominant forearm **6 to 12 months prior** to anticipated dialysis start to allow adequate vessel arterialization and maturation ($>6\text{ mm}$ diameter, $>600\text{ mL/min}$ blood flow, $<6\text{ mm}$ depth).
     - **AV Graft:** Synthetic PTFE conduit used when native veins are unsuitable; matures in 2–4 weeks but carries higher thrombosis and infection rates than fistulas.
     - **Central Venous Catheter (Tunneled CVC):** Highest risk of central vein stenosis, bacteremia, and sepsis; used only as bridge or emergency access.
  3. **Peritoneal Dialysis (PD):** Continuous Ambulatory PD (CAPD) or Automated PD (APD) via surgically placed Tenckhoff catheter into the peritoneal cavity.

> [!IMPORTANT]
> **The "Save the Veins" Rule in Stage G4/G5 CKD:**
> To preserve upper extremity venous vasculature for future AV fistula creation, the AGPCNP must educate the patient and clinical team to **strictly avoid venipunctures, peripheral IV lines, and PICC (peripherally inserted central catheter) lines** in the cephalic, basilic, and median cubital veins of the non-dominant arm (and preferably both upper extremities). Dorsal hand veins should be utilized for essential blood sampling.